MetaVia Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $3.4 million, or $0.14 per share, compared to a net loss of $5.7 million, or $0.55 per share, for the same period in 2024. The company’s total operating expenses decreased significantly to $3.5 million, down 44.5% from $6.3 million in the prior year, primarily due to reduced research and development (R&D) costs. R&D expenses for the quarter were $1.9 million, a decrease of 57.6% from $4.5 million in the previous year, reflecting lower activity in clinical trials for its product candidates Vanoglipel (DA-1241) and DA-1726.
For the nine months ended September 30, 2025, MetaVia reported a net loss of $11.0 million, or $0.63 per share, compared to a net loss of $22.4 million, or $3.24 per share, for the same period in 2024. Total operating expenses for the nine-month period were $11.7 million, a 49.8% decrease from $23.2 million in 2024. The reduction in expenses was attributed to a $10.9 million decline in R&D costs, which fell from $17.5 million to $6.6 million, as the company scaled back its clinical trial activities.
In terms of operational developments, MetaVia has been focusing on its two primary drug candidates, Vanoglipel and DA-1726, which target metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company is currently finalizing a Clinical Study Report for a Phase 2a trial of Vanoglipel and has initiated a Phase 1 trial for DA-1726. Additionally, MetaVia announced a research collaboration with Syntekabio, Inc. to enhance the therapeutic profile of Vanoglipel.
As of September 30, 2025, MetaVia had cash reserves of $14.3 million, down from $16.0 million at the end of 2024. The company has indicated that it expects to continue incurring losses and negative cash flows due to ongoing clinical trials, raising concerns about its ability to sustain operations without additional funding. MetaVia plans to explore various financing options, including equity offerings and collaborations, to support its operations moving forward. The company’s accumulated deficit stood at $146.9 million as of the end of the reporting period.
About MetaVia Inc.
MetaVia Inc. is a biotechnology company focused on developing pharmaceuticals for cardiometabolic diseases, including treatments for MASH and obesity. Its core programs include DA-1241, a GPR119 agonist for liver and diabetes, and DA-1726, a dual GLP-1 and glucagon receptor agonist for weight loss. The company advances its products through clinical trials, leveraging proprietary compounds, licensing agreements, and strategic collaborations in the biotech and pharmaceutical markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.